ArticleFrontiers in oncology2026
Bifidobacterium infantis-mediated HSV-TK/GCV therapy modulates the tumor microenvironment through site-specific phosphorylation of HIF-1α, mTOR, and PD-L1.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bifidobacterium (BF)-mediated herpes simplex virus thymidine kinase (TK)/ganciclovir (GCV) therapy has shown antitumor activity, but its effects on protein phosphorylation remain unclear. Methods: Quantitative phosphoproteomic analysis was performed on HCT-116 tumor xenografts to identify phosphorylation changes induced by BF-TK/GCV treatment. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted to explore the affected biological processes and signaling pathways. Immunohistochemistry (IHC) was used to validate the phosphorylation levels of key proteins. Additionally, RNA sequencing and IHC were applied to immunocompetent MC38 tumor-bearing mice to assess transcriptional changes and immune-related pathways. Results: Compared with the BF-TK group, BF-TK/GCV treatment resulted in 337 differentially abundant phosphopeptides (DAPs), and 108 DAPswere significantly altered relative to the BF/GCV group. GO analysis revealed enrichment in protein kinase activity, cell cycle regulation, and DNA replication. KEGG pathway analysis and IHC validation demonstrated that BF-TK/GCV differentially regulated the phosphorylation status of HIF-1α, mTOR, PKM2, and PD-L1 in a site-specific manner. Notably, IHC showed elevated immunoreactivity for several of these phosphoproteins in xenograft tumors, while phosphoproteomic comparisons also revealed decreased phosphopeptide abundance at other sites, indicating context-dependent modulation rather than uniform inhibition or activation. Notably, BF-TK/GCV suppressed tumor growth and significantly prolonged survival in tumor-bearing mice. Conclusions: Collectively, BF-TK/GCV does not uniformly inhibit or activate phosphorylation but rather reprograms the phosphoproteome in a site- and pathway-specific manner. These findings provide new insights into its therapeutic potential and suggest a promising strategy for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.